Popular
TWST · Medicine & biotech · U.S.

Twist Bioscience

Makes custom DNA for scientists using tiny silicon chips.

Company Health

49
/100
Mixed
A quick check of the business from its yearly reports (2022–2025). It doesn’t say whether the stock is a good buy.
Does it make money?
0 of 25 · Poor
It lost money last year: $21 of every $100 in sales.
Is it growing?
24 of 25 · Good
Sales grew about 23% a year over the last 3 years.
Can it handle what it owes?
25 of 25 · Good
It holds more cash than everything it owes.
Does it bring in spare cash?
0 of 25 · Poor
It spent more cash than it brought in: $20 of every $100 in sales.

Who owns it

None of the 23 funds we follow reported owning Twist Bioscience in their latest reports. Duquesne sold all their shares in their latest report.
bought lately
owns it
doesn’t own it
Didn’t report owning it: Whale Rock, Appaloosa, Melqart, Coatue, D1 Capital, Light Street, Lone Pine, Third Point, TCI, Pershing Square, Duquesne, Himalaya Capital, Greenlight, Giverny Capital, Fundsmith, Semper Augustus, Akre
Their letters don’t mention it: Arquitos, Laughing Water, Alluvial, Bireme, Kingdom Capital, Saga Partners
From each fund’s latest 13F report (Jun 30, 2026). Funds that don’t file one: from their own letters.

The numbers

From Twist Bioscience’s yearly reports. Tap a year to see its figures.

Sales and profit

Sales grew from $90.1 million in the year to Sep 2020 to $377 million in the year to Sep 2025, and it lost money every year.
FY2025
Sales
$377 million
Loss
$77.7 million

Spare cash each year

It spent more cash than it brought in every year: $75.6 million more in the year to Sep 2025.
FY2025
Cash shortfall
$75.6 million
Spare cash is the cash its business brought in, minus what it spent on buildings and equipment.

What it owns and what it owes

At the end of Sep 2025 it owned $642 million, including $183 million in cash, and owed $169 million.

Key facts

From its yearly report for the year to Sep 2025.
Sales
$377 million
Loss
$77.7 million
Cash shortfall
$75.6 million
Cash in the bank
$183 million
Everything it owes
$169 million
Year ends
September
Money shown in
U.S. dollars
Latest yearly report
10-K, filed Nov 17, 2025
Figures from Twist Bioscience’s yearly reports to the SEC (EDGAR), collected Oct 12, 2026.
Not investment advice. Holdings come from public SEC reports and the funds’ own letters, and can be up to 4½ months old. How this works
Privacy policy